Live Breaking News & Updates on Covovax vaccine

Stay informed with the latest breaking news from Covovax vaccine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Covovax vaccine and stay connected to the pulse of your community

Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

Uttar-pradesh , India , Tamil-nadu , Adar-poonawalla , Adar-poonawalla-serum-institute , Centre-on , Serum-institute-of-india , Current-covid-strain-mild , Covovax-doses-made , Serum-institute , India-covid-cases , Covovax-vaccine

Novavax: The Vaccine Battle Continues With Gavi (NASDAQ:NVAX)

NVAX may remain volatile in the short term due to the $700M Advance Purchase Agreement dispute with GAVI. Click here to read my most recent analysis of NVAX.

New-york , United-states , Australia , New-zealand , Thailand , India , Netherlands , China , South-africa , Indonesia , Canada , South-korea

COVID-19 update: SII drops price of its Covovax vaccine

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group, subject to certain conditions, on March 9.

India , Prakash-kumar-singh , Regulatory-affairs , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Serum-institute , National-technical-advisory-group , Bharat-biotech , Covid-vaccine , Vaccine , Covid-19-vaccine , Novavax

COVID-19 update: Covovax now available for children in India, says Adar Poonawalla

Poonawalla said, "This is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of > (more than) 90%."

India , Narendra-modi , Adar-poonawalla , Twitter , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Serum-institute , Prime-minister-narendra-modi , National-technical-advisory-group , Bharat-biotech , Covovax , Covavax-for-india

Covovax Vaccine Now Available For 12-17 Age Group At Private Centres

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.

India , Pune , Maharashtra , Union-health-ministry , Age-group-at-private-centres-covovax , Services-tax , Serum-institute , Regulatory-affairs-prakash-kumar-singh , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Covovax-vaccine-now-available-for

NTAGI Approves SII's Covovax COVID-19 Vaccine for 12-17 Age Group: Sources

Earlier this month in an Exclusive Interview with ANI, Serum Institute of India (SII) CEO Adar Poonawalla said, "Covovax will be used for children. It has been approved by DCGI and we're waiting for the Government of India to allow us to put it on the CoWIN app to make it available to everyone." NTAGI Approves SII's Covovax COVID-19 Vaccine for 12-17 Age Group: Sources.

Australia , India , New-delhi , Delhi , Bharat , Narendra-modi , Adar-poonawalla , Adar-poonawala , Serum-institute-of-india-covovax , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , National-technical-advisory-group

Serum Institute CEO Adar Poonawalla Hails WHO's Approval Of Covovax Vaccine For Emergency Use For Children

Serum Institute of India (SII) CEO Adar Poonawalla on Friday hailed WHO's approval for emergency use of Covovax vaccine for children "as yet another milestone" in the fight against COVID-19.

India , Seth-berkley , Adar-poonawalla , Serum-institute-adar-poonawalla-hails , Covovax-vaccine-serum-institute , World-health-organization , Technical-advisory-group-for-emergency-use-listing , Gates-foundation , Vaccine-alliance , Serum-institute-of-india , Serum-institute , Adar-poonawalla-hails

soon clinical trial of corona vaccine covovax will be on children serum institute of india will apply to dcgi aml | जल्द ही बच्चों पर होगा कोरोना वैक्सीन Covovax का क्लिनिकल ट्रायल, सीरम DCGI के पास करेगा आवेदन

नयी दिल्ली : सबसे बड़ी वैक्सीन निर्माता कंपनी सीरम इंस्टीट्यूट ऑफ इंडिया (SII) अपने दूसरे वैक्सीन (Corona Vaccine) कोवोवैक्स (Covovax) का बच्चों पर परीक्षण की तैयारी कर रहा है. इसके लिए सीरम जल्द ही भारत के ड्रग कंट्रोलर के पास आवेदन कर सकता है. इंडियन एक्सप्रेस की एक खबर के मुताबिक कोवोवैक्स का 18 प्लस के लोगों को तीसरे फेज का ट्रायल 18 जून को शुरू हुआ था. इस वैक्सीन का विकास सीरम यूएस की कंपनी नोवावैक्स इंक के साथ मिलकर कर रहा है. | नयी दिल्ली : सबसे बड़ी वैक्सीन निर्माता कंपनी सीरम इंस्टीट्यूट ऑफ इंडिया (SII) अपने दूसरे वैक्सीन (Corona Vaccine) कोवोवैक्स (Covovax) का बच्चों पर परीक्षण की तैयारी कर रहा है. इसके लिए सीरम जल्द ही भारत के ड्रग कंट्रोलर के पास आवेदन कर सकता है. इंडियन एक्सप्रेस की एक खबर के मुताबिक कोवोवैक्स का 18 प्लस के लोगों को तीसरे फेज का ट्रायल 18 जून को शुरू हुआ था. इस वैक्सीन का विकास सीरम यूएस की कंपनी नोवावैक्स इंक के साथ मिलकर कर रहा है.

India , Pune , Maharashtra , Clinical-trial , Corona , Corona-vaccine , Covishield , Covovax , Novavax , Covovax-vaccine , Covovax-corona-vaccine

Third coronavirus vaccine in India? Adar Poonawalla hopes to launch COVOVAX by June

Serum Institute of India CEO Adar Poonawalla said the company's tie-up with American vaccine developer Novavax has published 'excellent efficacy results'

United-states , India , United-kingdom , Pune , Maharashtra , American , Bharat , Adar-poonawalla , Union-health-ministry , Serum-institute , Serum-institute-of-india , Drugs-controller-general